Axonis Therapeutics
Boston, US · Founded 2019 · Delaware corporation · 13 known investors
Axonis Therapeutics is a drug discovery company developing first-in-class therapies for currently incurable neurological disorders. It focuses on advancing treatments for patients with neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Founders & leadership
Axonis Therapeutics was founded in 2019 by Shane Hegarty and Shane V. Hegarty.
SH
Shane HegartyCo-founder
SV
Shane V. HegartyChief Scientific Officer & Co-Founder
JI
Jeffrey ImbaroExecutive
JS
Joanna StanickaChief Executive Officer, President & Co-Founder
JI
Jeff ImbaroChief Operating Officer
TS
Tiasha ShafiqChief of Staff
Board
C.
JL
RJ
Raymond J. KelleherBoard director
DM
Donald Manning, M.D., Ph.Dr
BR
Brock ReeveBoard director
Investors · 13
Civilization Ventures Management, LlcTiburon · $1M – $10M
Creative Destruction Lab (CDL)Toronto · $50K – $250K
Hatteras Venture PartnersResearch Triangle · $500K – $4M
Iaso VenturesCambridge
Lumira VenturesToronto · $1M – $10M
Pathway BioventuresChicago
SCI VenturesLondon
Solasta VenturesBoston
Tachyon VenturesLos Angeles
venBio PartnersSan Francisco
BoxOne VenturesreportedMontréal · $500K
Sofinnova VenturesreportedMenlo Park · $100K – $15M
venBio Global StrategicreportedSan Francisco
Reported raises · per SEC filings
Form D private placements$46M disclosed across 1 round · 2024
▶$46MraisedNov 2024 · 19 investors · BiotechnologyRule 506(b)
▶$46MraisedNov 2024 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Donald Manning, M.D., Ph.DExecutive Officer
- Jeffrey ImbaroExecutive Officer
- Corey . GoodmanDirector
- Brock ReeveDirector
- Shane HegartyExecutive Officer
- Joanna StanickaExecutive Officer, Director
- Jonathan LeffDirector
- Raymond J. KelleherDirector
- Offering amount
- $115M
- Amount sold
- $46M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Axonis Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $299.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $335.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $298.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $330.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Axonis Therapeutics do?
- Axonis Therapeutics is a drug discovery company developing first-in-class therapies for currently incurable neurological disorders. It focuses on advancing treatments for patients with neurological diseases.
- Who founded Axonis Therapeutics?
- Axonis Therapeutics was founded by Shane Hegarty, Shane V. Hegarty in 2019.
- Who are Axonis Therapeutics's investors?
- Axonis Therapeutics's investors include Civilization Ventures Management, Llc, Creative Destruction Lab (CDL), Hatteras Venture Partners, Iaso Ventures, Lumira Ventures, Pathway Bioventures, SCI Ventures, Solasta Ventures and 5 more.
- How much funding has Axonis Therapeutics raised?
- Axonis Therapeutics has disclosed $46M raised across 1 round.
- Where is Axonis Therapeutics headquartered?
- Axonis Therapeutics is headquartered in Boston, US.